Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProMetic Plasminogen in Hypoplasminogenemia
NCT02312180Phase 1Completed
- Sponsor
- Prometic Biotherapeutics Ltd
- Start
- Dec 2014
- Primary completion
- Dec 2015
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of plasminogen in hypoplasminogenemia (HPG) (3 cohorts), sponsored by Prometic Biotherapeutics Ltd. Primary endpoint: Pharmacokinetic profile of lyophilized plasminogen at 8 months. Started Dec 2014; status: completed.
02
Drugs
plasminogen
03
Conditions
hypoplasminogenemia (HPG)
Beyond the preview
Go deeper on NCT02312180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02312180.